RepliCel Life Sciences Inc’s Stock Is Sell After Today’s Huge Decline

 RepliCel Life Sciences Inc's Stock Is Sell After Today's Huge Decline

The stock of RepliCel Life Sciences Inc (CVE:RP) is a huge mover today! About 69,758 shares traded hands or 194.82% up from the average. RepliCel Life Sciences Inc (CVE:RP) has risen 6.00% since October 1, 2016 and is uptrending. It has outperformed by 2.53% the S&P500.
The move comes after 6 months negative chart setup for the $6.76M company. It was reported on Oct, 31 by Barchart.com. We have $0.86 PT which if reached, will make CVE:RP worth $676,000 less.

More important recent RepliCel Life Sciences Inc (CVE:RP) news were published by: Marketwired.com which released: “RepliCel Life Sciences Announces Closing of Private Placement” on October 31, 2016, also Marketwired.com published article titled: “RepliCel Life Sciences Announces Completion of the Final Injection in Its …”, Marketwired.com published: “RepliCel Life Sciences Amends Terms of Private Placement” on October 07, 2016. More interesting news about RepliCel Life Sciences Inc (CVE:RP) was released by: Midasletter.com and their article: “RepliCel Life Sciences Inc. CEO David Hall Interview and Podcast” with publication date: October 23, 2014.

RepliCel Life Sciences Inc. is a regenerative medicine firm focused on developing autologous cell therapies that treat functional cellular deficits. The company has a market cap of $6.76 million. The Company’s product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. It currently has negative earnings. RCT-01 is an autologous cell treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment